Alberta Prostate Biorepository, Canada

Certification Status: Approved

Registration Status: Completed

Objective: - To develop and maintain infrastructure in Edmonton and Calgary to longitudinally collect: 1) biospecimens, including blood, urine, semen, tissue (when applicable); 2) clinical information pertaining to the management of prostate cancer and other health-related events; and 3) patient-reported health quality-of-life and symptoms from patients with confirmed prostate cancer across Alberta; - To identify, evaluate and validate a range of potential biomarkers for prognostic (disease outcomes) and predictive (treatment outcomes) potential in the detection and management of prostate cancer; - To support health research that makes use of biospecimens in conjunction with clinical and patient-reported outcome data to discover novel molecular markers relevant to the care and management of patients.

Registered Biobank Name	Alberta Prostate Biorepository
Biobank Leader	Catalina Vasquez
Country	Canada
Email for biobank inquiries	catalina.vasquez@ualberta.ca
Principal Investigator	John D lewis, Bryan Donnelly and Adrian Fairey
Website	www. APCaRI.ca
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Oligo - Collection aimed at supporting several research projects, a research group or a research consortium

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).